Physician profile
Syma Iqbal
NPI 1518982206
$178,469.50
in general payments reported to CMS, 2019-2025
16 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,891 · 2020: $2,045 · 2021: $11K · 2022: $9,558 · 2023: $39K · 2024: $53K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $46K · Travel and Lodging: $8,064 · Honoraria: $3,000 · Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,070.00 |
| Consulting Fee | $46,332.71 |
| Travel and Lodging | $8,063.70 |
| Honoraria | $3,000.00 |
| Food and Beverage | $2,423.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $94,870.90 | 2023-2025 | Vyloy |
| Merck Sharp & Dohme LLC | $24,084.19 | 2019-2025 | Lenvima, Keytruda |
| Beigene USA, INC. | $16,550.95 | 2024-2025 | Tevimbra |
| Beone Medicines USA, INC. | $14,342.43 | 2025 | Tevimbra, Brukinsa |
| Beigene, Ltd. | $8,085.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $4,394.50 | 2021-2022 | |
| Exelixis INC. | $4,208.72 | 2024 | Cabometyx |
| Celgene Corporation | $3,827.21 | 2019 | |
| Jazz Pharmaceuticals INC. | $3,531.83 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $2,000.00 | 2020 | |
| Eisai INC. | $1,274.90 | 2020-2021 | |
| Daiichi Sankyo INC. | $1,271.45 | 2022 | |
| Amgen INC. | $27.42 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syma Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.